 Connection
Scot Sedlacek to Tamoxifen
This is a "connection" page, showing publications Scot Sedlacek has written about Tamoxifen.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.136 |
|
|
|
-
Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaughnessy JA. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Res Treat. 2009 Aug; 116(3):521-7.
Score: 0.067
-
Leonard CE, Wood ME, Zhen B, Rankin J, Waitz DA, Norton L, Howell K, Sedlacek S. Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? J Clin Oncol. 1995 Dec; 13(12):2906-15.
Score: 0.027
-
Sedlacek SM. An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):3-13.
Score: 0.016
-
Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005 Jun 01; 23(16):3686-96.
Score: 0.013
-
Sedlacek SM, Horwitz KB. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids. 1984 Dec; 44(6):467-84.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|